Immune Checkpoint Inhibitors Market

Market Size

The global immune checkpoint inhibitors market, valued at USD 75 billion in 2025, is projected to reach USD 82 billion in 2026 and USD 146 billion by 2035, with a 6.6% CAGR during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

• Immune checkpoint inhibitors market is growing dynamically due to the growing awareness of its ability to generate natural immune response against cancer cells.
• In terms of immune checkpoint proteins, the PD-1 segment secured 70% of the overall revenue share due to its higher efficacy in targeting non-small cell lung cancer, melanoma, and renal cancer.
• By target disease indication, the lung cancer segment occupies 29% of the market share. This dominance stems from the increasing usage of immune checkpoint inhibitors to treat lung cancer.
• Based on the type of modality, the monoclonal antibodies segment is dominating by holding 70% of the revenue share.

• On the basis of geographical regions, the North America secures 56% of the market share due to the increasing research on immune checkpoint blockade therapy to treat cancer.

Market Introduction

Immune checkpoint inhibitors refers to the drug class that enhance the natural immune response of the body against tumor. These inhibitors block specific type of proteins that inhibit immune activation. Owing to its capability to enhance immune response, it is widely used for the treatment of cancers, such as lung cancer, melanoma, and bladder cancer. It is important to note here that the rising incidence of cancer has necessitated the demand for target specific therapeutic treatment. These immune checkpoint inhibitors have transformed the cancer treatment by enhancing body’s own immune response, opening pathways for the patients who are not responding to conventional therapies.

Considering the target efficacy, several research organizations and market players are undertaking strategic initiatives to explore potential immune checkpoint inhibitors to target wide range of cancer. Notably, in October 2025, the USFDA has approved cemiplimab-rwlc (Libtayo®) developed by Regeneron Pharmaceuticals (US) to treat adults with cutaneous squamous cell carcinoma who are also having high risk of recurrence after radiation therapies and surgery. Owing to the ongoing demand for advanced immunotherapies and accelerated regulatory approvals for new checkpoint inhibitor drugs from the USFDA, it is expected that the immune checkpoint inhibitors market will remain progressive in the upcoming years.

Recent Developments in Immune Checkpoint Inhibitors Market

• In August 2025, the USFDA has approved an investigational new drug application for ABT – 301 (a HDAC1 / 2/ 3 inhibitor with immune -modulating capabilities) developed by Anbogen Therapeutics (Taiwan). This approval has cleared the way for the initiation of phase 1 / 2 clinical trial for the drug in combination with Avastin® (bevacizumab), and Tevimbra® (tislelizumab) to treat patients with metastatic colorectal cancer.
• In June 2025, Pembrolizumab, an immune checkpoint inhibitor was approved by the USFDA to treat patients with resectable locally advanced head and neck squamous cell carcinoma who tumor express PD-L1.
• In April 2025, the USFDA has approved the combination of ipilimumab (Yervoy®) and nivolumab (Opdivo®) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma. The approval mark a significant milestone to expand the use of dual immune checkpoint inhibitors in liver cancer.

Market Trends

• Combination Therapies with Checkpoint Inhibitors: Several clinical studies have shown that immune checkpoint inhibitors have shown higher efficacy when used in combination with targeted therapies. For instance, MEK / BRAF inhibitors in melanoma target cancer-driving mutations and anti-angiogenic agents in renal cell carcinoma inhibit blood vessel growth. Owing to the higher efficacy, researchers are exploring personalized oncology using immune checkpoint blockade in combination with other therapeutics which is driving research and development activities in this market.
• Expanding Usage for Wide Range of Indication: Researchers are also exploring immune checkpoint inhibitors beyond melanoma and lung cancer. The future focus will be on the development of personalized therapies by using immune checkpoint inhibitors to treat cervical cancer, bladder cancer, colorectal cancer and other cancers.
• Future Focus on Biomarker-Driven Immunotherapy: In order to ensure better treatment outcomes, the market players are emphasizing the integration if advanced cancer biomarkers for response to immune checkpoint inhibitor drugs  including tumor mutational burden (TMB), PD-L1 expression, and microsatellite instability-high (MSI-H) status. Moreover, the future focus will be on investigation of genomic hypermutation biomarkers, such as mutations in POLE and POLD DNA polymerase to enhance immune checkpoint inhibitors efficacy.

Industry Experts on Immune Checkpoint Inhibitors Market

Experts believe that immune checkpoint inhibitors in cancer treatment have a broad scope and progress in the future.

John E. Dick (American Association for Cancer Research Hematologic Malignancies Working Group Committee Member) says that ‘It’s become clear that clonal hematopoiesis is influencing how immune checkpoint inhibitor therapy works in certain subsets of patients. We already know that there’s often crosstalk between a solid tumor and the blood system or the immune system, but now there is work that implicates clonal hematopoiesis as another factor that has been previously unrecognized. This is a going to become a major player in how patients with any kind of solid tumor will respond to therapy.’

Immune Checkpoint Inhibitors Market Drivers

• Rising Incidence of Cancer: The increasing global burden of cancer has necessitated the demand for immune checkpoint inhibitors based therapies. It is worth noting that the immune checkpoint inhibitors market growth is further driven by the growing approval of the immune checkpoint inhibitors from the USFDA.
• Increasing Adoption as First-Line Therapies: Immune checkpoint inhibitors are increasingly adopted as first-line therapy to treat non-small cell lung cancer and other form of cancers. Owing to its increasing adoption for targeting immune checkpoint inhibitors for solid tumor treatment, there will be surge in the demand for these targeted therapies.
• Continuous Research on Immune Checkpoint Inhibitors: The market players are continually investing in research and development initiatives to explore next-generation targets. Their primary focus is on finding the appropriate solution to overcome the acquired checkpoint inhibitor resistance to recently available immune checkpoint inhibitors.

Market Segmentation Analysis

PD-1 Will Remain Dominant in the Future

• Based on the type of immune checkpoint proteins, the global market is segmented into PD-1, PD-L1, CTLA-4, and others. According to our immune checkpoint market report, the PD-1 segment dominates the market due to the higher efficacy in targeting tumor cells. Additionally, PD-1 is widely used in combination with broad range of cancer therapeutics, such as targeted therapies, chemotherapy, and CTLA-4 inhibitors, which is expected to drive its demand.
• It is important to note here that the PD-L1 segment is likely to show robust growth, anticipated to register higher CAGR. This lucrative growth stems from the higher efficacy of PD-L1 inhibitors, such as Avelumab (Bavencio®), and Atezolizumab (Tecentriq™), and Durvalumab (Imfinzi®) in treating metastatic merkel-cel carcinoma.

Immune Checkpoint Inhibitors Will Continue to Gain Traction for Lung Cancer Treatment

• This segment is sub-divided across different target disease indication, such as lung cancer, breast cancer, bladder cancer, cervical cancer, colorectal cancer, melanoma, hodgkin lymphoma, and others. Among these, the lung cancer segment is dominating by securing 29% of the overall immune checkpoint inhibitors market share.
• Notably, the colorectal cancer segment is likely to grow at a higher CAGR during the forecast period. This is likely to be the result of increasing prevalence of colorectal cancer and heightened research on combination therapies using CTLA-4 and PD-1 inhibitors to explore its usage beyond lung cancer treatment.

Intravenous Route of Administration is Most Preferred to Deliver Immune Checkpoint Inhibitors

• Based on the route of administration, this segment is sub-divided into intravenous, subcutaneous, intracellular, and others. According to the immune checkpoint inhibitors market analysis, the intravenous segment dominates the market, and the trend is likely to remain unchanged in the future. This dominance stems from the widespread adoption of intravenous route of administration due to its higher efficacy.
• It is important to highlight here that this segment will continue to remain dominant and is likely to grow at a higher CAGR during the forecast period. This lucrative growth is due to its higher efficacy and safety in delivering drug at targeted sites.

Market Regional Insights

North America Dominates the Immune Checkpoint Inhibitors Market

According to the immune checkpoint inhibitors market forecast, the North America region dominates the market by securing 56% of the market share. This dominance is due to the favorable regulatory policy for the research and development of novel PD-1 / PD-L1 immune checkpoint inhibitor therapies and rising prevalence of cancer.

US Immune Checkpoint Inhibitors Market

The market for immune checkpoint inhibitors in US is likely to grow substantially and is likely to remain progressive in the future. Several factors, such as high incidence of cancer and increasing diagnosis of cancer in the US to treat people at early stage. Additionally, the presence of well-established industrial players and increasing immune checkpoint inhibitor clinical trials has further strengthened the market growth in this region.

Immune Checkpoint Inhibitor Market Trends in Asia-Pacific

In Asia-pacific, the market is expected to grow at the fastest CAGR during the forecast period. This growth is primarily fueled by the surge in the incidence of cancer and increasing investment by government organizations in advanced healthcare infrastructure to support cancer treatment. It is important to mention here that the Asian countries, such as China and India are supporting research organizations to explore combination and next generation immune checkpoint inhibitors which further accelerating the market growth in this region.

It is important to note here that the Guangzhou Gloria Biosciences (China) has received China National Medical Products Administration (NMPA) approval for the Zimberelimab® injection. It is a monoclonal antibody that directly binds to the PD-1, and immune checkpoint for anti-cancer immunity. This accelerated approval has further supported the market growth in the Asian region.

Immune Checkpoint Inhibitors Market: Report Attributes / Market Segmentation

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2026	USd 82 Billion
Market Size 2035	USD 146 Billion
CAGR (Till 2035)	6.6%
Segments Covered	Immune Checkpoint Proteins Target Disease Indication Therapeutic Modality Route of Administration Geographical Regions
Key Players Profiled	AstraZeneca (UK) BeiGene (China) Bristol-Myers Squibb (US) Eli Lilly (US) GlaxoSmithKline (UK) Immutep (Australia) Merck (US) Novartis (US) Regeneron Pharmaceuticals (US) Roche (Switzerland) Sanofi (France) Shanghai Jhunsi Biosciences (China) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

Market Segmentation

Based on the immune checkpoint inhibitors industry analysis, we have segmented the immune checkpoint inhibitors market into type of immune checkpoint proteins, target disease indication, type of therapeutic modality, route of administration, geographical regions, and leading players.

Immune Checkpoint Inhibitors Market, by Type of Immune Checkpoint Proteins

• PD-1
• PD-L1
• CTLA-4
• Others

Immune Checkpoint Inhibitors Market, by Target Disease Indication

• Lung Cancer
• Breast Cancer
• Bladder Cancer
• Cervical Cancer
• Colorectal Cancer
• Melanoma
• Hodgkin Lymphoma
• Others

Immune Checkpoint Inhibitors Market, by Type of Therapeutic Modality

• Antibody Fragments
• Monoclonal Antibodies
• Small Molecules
• Other Modalities

Immune Checkpoint Inhibitors Market, by Route of Administration

• Intravenous
• Subcutaneous
• Intracellular
• Others

Immune Checkpoint Inhibitors Market, by Geographical Regions

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • New Zealand
  • Rest of the Asia-Pacific
• Middle East & Africa
  • Egypt
  • Iran
  • Iraq
  • Israel
  • Saudi Arabia
  • South Africa
  • United Arab Emirates
• Latin America
  • Argentina
  • Brazil

Frequently Asked Questions

Question 1: What are immune checkpoint inhibitors?

Answer: Immune checkpoint inhibitors refers to the type of immunotherapy that block proteins known as checkpoints on immune cells. These immune checkpoint inhibitors allow immune system to attack cancerous cells with higher efficacy.

Question 2: How big is the immune checkpoint inhibitor market?

Answer: The immune checkpoint inhibitors market size is valued at USD 82 billion in 2026.

Question 3: What companies make immunotherapy?

Answer: AstraZeneca (UK), BeiGene (China), Bristol-Myers Squibb (US), Eli Lilly (US), GlaxoSmithKline (UK), Immutep (Australia), Merck (US), Novartis (US), Regeneron Pharmaceuticals (US), Roche (Switzerland), Sanofi (France), and Shanghai Jhunsi Biosciences (China).

Question 4: What pharma company makes Keytruda?

Answer: Merck (US) is the pharmaceutical company who made Keytruda.

Question 5: What are the most common checkpoint inhibitors?

Answer: PD-1, PD-L1, and CTLA-4 proteins are some of the common checkpoint inhibitors that are commonly used to target cancer cells.

Question 6: Which immune checkpoint inhibitors are FDA approved?

Answer: Anti-PD-1 drugs, such as nivolumab, pembrolizumab, and cemiplimab, and anti-CTLA-4 drugs, such as tremelimuab, and ipilimumab, and anto-PD-L1 drugs, such as durvalumab, avelumab, and atezolizumab, and Relatlimab, and anti-LAG-3 inhibitor are some of the immune checkpoint inhibitors that are approved by the FDA.

Question 7: What immune checkpoint inhibitors are FDA approved 2025?

Answer: ipilimumab (Yeovoy®) and nivolumab (Opdivo®) are some of the immune checkpoint inhibitors that are approved by the USFDA in 2025.